Wall Street Top Analysts' Latest Ratings: Coty Downgraded

Deep News2025-12-23

Here’s a summary of the most talked-about analyst ratings on Wall Street that could influence market trends. Below are the key rating adjustments investors should watch today.

**Key Upgrades** ▸ TD Cowen upgraded Ametek (AME) from 'Hold' to 'Buy,' raising the price target from $180 to $230. The firm noted that Ametek's backlog remains at historically high levels and is expected to grow further, signaling an inflection point in both orders and revenue. ▸ Piper Sandler upgraded SEI Investments (SEIC) from 'Neutral' to 'Overweight,' increasing the price target from $93 to $102. This adjustment reflects the firm's Q4 outlook for the asset management sector, with SEI positioned to benefit from the expansion of alternative asset management. ▸ CFRA strengthened its bullish stance on Pool Corp. (POOL), upgrading it from 'Hold' to 'Buy' with a $304 price target.

**Key Downgrades** ▸ Evercore ISI downgraded Coty (COTY) from 'Outperform' to 'In-Line,' setting a $7 price target. The firm cited CEO Sue Nabi as a key pillar of the investment thesis but noted the lack of a clear timeline for value realization or catalysts. Santander also downgraded Coty to 'Neutral' with a $3.50 target. ▸ BMO Capital downgraded Brown & Brown (BRO) from 'Outperform' to 'Market Perform,' lowering the target from $90 to $88, citing downward revisions to 2026 organic growth expectations. ▸ Piper Sandler downgraded Cleanwater Analytics (CWAN) from 'Overweight' to 'Neutral,' adjusting the target to $24.55 (the acquisition price by a Permira/Warburg Pincus-led consortium). ▸ TD Cowen downgraded Janus Henderson (JHG) from 'Buy' to 'Hold' with a $49 target, aligning with its pending all-cash acquisition by Trian/General Atlantic for $74B ($49/share).

**Key Initiations** ▸ Oppenheimer initiated coverage on Spruce Biosciences (SPRB) with an 'Outperform' rating and $283 target, citing FDA-recognized biomarker data and Breakthrough Therapy designation for its MPS II drug. ▸ LifeSci Capital initiated coverage on Sion Therapeutics (SION) with an 'Outperform' rating and $60 target, highlighting its pipeline, including SION-719 (NBD1 stabilizer) and dual-drug combos. ▸ Oppenheimer also initiated Aardvark Therapeutics (AARD) with an 'Outperform' rating and $35 target, citing its differentiated obesity drug pipeline. ▸ JonesResearch initiated coverage on Septenor Biopharma (SEPN) with a 'Buy' rating and $43 target, projecting $2.5B peak sales for its hypoparathyroidism drug SEP-479. It also initiated ATAI (ATAI) and MindMed (MNMD) as 'Buy.' ▸ Loop Capital initiated Malibu Boats (MBUU) with a 'Buy' rating and $34 target, noting the boating industry's inventory normalization cycle. It also initiated Brunswick (BC) and MasterCraft (MCFT) as 'Hold.'

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment